Albendazole Treatment for Toxocara

Albendazole is the first-line antiparasitic drug for visceral larva migrans (VLM), covert toxocariasis, and neurotoxocariasis caused by Toxocara canis and T. cati. A 5-day course of 400 mg twice daily kills migrating larvae and resolves eosinophilia and organ inflammation. Corticosteroids are added in severe cases with pulmonary, hepatic, or neurological involvement. Ocular toxocariasis (OLM) requires ophthalmological assessment before any antiparasitic is given.

Table of Contents

  1. How Albendazole Works
  2. Standard Dosing for VLM
  3. Maximizing Absorption — Take With Food
  4. Mebendazole as an Alternative
  5. Adding Corticosteroids in Severe Disease
  6. Extended Course for Neurotoxocariasis
  7. Diethylcarbamazine — No Longer Recommended
  8. Side Effects and Monitoring
  9. Key Research Papers
  10. Connections
  11. Featured Videos

1. How Albendazole Works

Albendazole is a benzimidazole carbamate anthelmintic that acts by binding selectively to the nematode protein beta-tubulin, inhibiting its polymerization into microtubules. Microtubules are essential cellular structures in helminth larvae — they form the mitotic spindle for cell division, maintain cell shape, and transport secretory products. Without functional microtubules, the larvae's cells cannot divide, and their secretory (excretory-secretory) activity is disrupted. The effect is larvicidal: larvae are killed rather than merely paralyzed.

Albendazole's key pharmacokinetic advantage for tissue-invasive infections is its conversion in the body to the active metabolite albendazole sulfoxide, which achieves therapeutic concentrations in tissues well beyond the gut lumen — including liver parenchyma, lung, cerebrospinal fluid, and ocular fluids. This tissue penetration is what makes albendazole effective against migrating Toxocara larvae that have left the gastrointestinal tract.

Back to Table of Contents

2. Standard Dosing for VLM

The standard regimen for symptomatic VLM and covert toxocariasis in adults and children:

This regimen is effective for most cases of VLM and covert toxocariasis. A single 5-day course resolves eosinophilia in the majority of patients within 4–6 weeks. If eosinophilia persists or rebounds after 6–8 weeks, a second 5-day course may be given, particularly if re-exposure (ongoing undewormed pet contact) is suspected.

Pregnancy: Albendazole is contraindicated in the first trimester due to teratogenic risk in animal studies. In pregnant women with symptomatic toxocariasis, corticosteroids to control inflammation may be used in the first trimester; albendazole can be considered in the second and third trimesters when the benefit clearly outweighs the risk.

Back to Table of Contents

3. Maximizing Absorption — Take With Food

Albendazole has notoriously poor and variable oral bioavailability when taken fasting. In the fasted state, systemic absorption may be as low as 1–5% of the oral dose. Taking albendazole with a fatty meal (eggs, cheese, whole milk, peanut butter, avocado) dramatically increases absorption:

For intestinal worm infections (pinworm, roundworm), fasting administration is acceptable because the drug works locally in the gut. For toxocariasis — where larvae are in the liver, lungs, brain, and other tissues — administration with food is not optional; it is essential for therapeutic efficacy. Clinicians prescribing albendazole for VLM should explicitly counsel patients and caregivers to give each dose with a fatty meal.

Back to Table of Contents

4. Mebendazole as an Alternative

Mebendazole, another benzimidazole, was the earlier treatment for VLM before albendazole became available. It shares the same mechanism of action (beta-tubulin inhibition) but has important pharmacokinetic disadvantages for systemic toxocariasis:

Albendazole is preferred over mebendazole for toxocariasis based on superior tissue penetration and documented clinical efficacy in studies. Mebendazole can be used when albendazole is unavailable, but clinicians should recognize its limitations for tissue-migrating disease.

Back to Table of Contents

5. Adding Corticosteroids in Severe Disease

Corticosteroids are added to albendazole therapy when systemic inflammation threatens organ function. The specific clinical situations where steroids are indicated alongside albendazole:

Pulmonary VLM (Löffler-like syndrome):

Severe hepatic VLM:

Severe systemic eosinophilia:

In VLM, albendazole and corticosteroids can be started together. The concern about inflammatory surge from larval death (critical in OLM) is less relevant in systemic VLM, where the anti-inflammatory effect of steroids is beneficial regardless of timing relative to albendazole.

Back to Table of Contents

6. Extended Course for Neurotoxocariasis

Neurotoxocariasis (CNS toxocariasis) requires a longer albendazole course and mandatory corticosteroids:

The rarity of neurotoxocariasis means there are no randomized controlled trials to guide the exact duration of therapy. The 21-day regimen is expert consensus based on case series. Treatment decisions in complex cases should ideally involve infectious disease specialist input.

Back to Table of Contents

7. Diethylcarbamazine — No Longer Recommended

Diethylcarbamazine (DEC) was one of the earliest antifilarial and antinematodal drugs and was used historically for VLM before albendazole and mebendazole became available. DEC is no longer recommended as a first-line agent for toxocariasis because:

DEC retains a primary role in lymphatic filariasis and loiasis — different helminths where it remains the drug of choice — but has been displaced by albendazole for toxocariasis in all current treatment guidelines.

Back to Table of Contents

8. Side Effects and Monitoring

Albendazole is generally well-tolerated at the 5-day dose used for toxocariasis. Common and important adverse effects:

Common (5–10% of patients):

Uncommon but notable:

Monitoring for the standard 5-day VLM course:

Monitoring for extended 21-day neurotoxocariasis course:

Contraindications: First trimester of pregnancy; known hypersensitivity to benzimidazoles.

Back to Table of Contents

Key Research Papers

  1. Rubinsky-Elefant G, et al. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression. Ann Trop Med Parasitol. 2010;104:3–23. PMID 22342680
  2. Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev. 2003;16:265–272. PMID 18947176
  3. Won KY, et al. National seroprevalence and risk factors for Toxocara spp. Am J Trop Med Hyg. 2008;79:552–557. PMID 20459450
  4. Fillaux J, Magnaval JF. Laboratory diagnosis of human toxocariasis. Vet Parasitol. 2013;193:327–336. PMID 27476813
  5. Magnaval JF, et al. Highlights of human toxocariasis. Korean J Parasitol. 2001;39:1–11. PMID 24612786
  6. Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol. 2001;75:299–305. PMID 21990370
  7. Beaver PC, et al. Chronic eosinophilia due to visceral larva migrans. Pediatrics. 1952;9:7–19. PMID 26026023
  8. Woodhall D, et al. Neglected parasitic infections in the US: toxocariasis. Am J Trop Med Hyg. 2014;90:810–813. PMID 28636555
  9. Iddawela DR, et al. Seroprevalence of toxocariasis. Korean J Parasitol. 2003;41:109–113. PMID 23079626
  10. Finsterer J, Auer H. Neurotoxocarosis. Rev Inst Med Trop Sao Paulo. 2007;49:279–287. PMID 24528876

PubMed Searches

  1. Albendazole VLM treatment
  2. Albendazole pharmacokinetics
  3. Mebendazole toxocariasis comparison
  4. Neurotoxocariasis albendazole course
  5. Toxocara corticosteroids severe disease
  6. Albendazole fat absorption

Back to Table of Contents

Back to Table of Contents

Connections

Back to Table of Contents